Citigroup’s Edesa Biotech EDSA Stock Holding History

Citigroup’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-487	Closed	-$2.55K	–	5865
2026 Q1	$2.55K	Buy	+487	New	+$1.46K	﹤0.01%	5395
2025 Q4	–	Sell	-2,000	Closed	-$4.88K	–	6153
2025 Q3	$4.88K	Buy	+2,000	New	+$4.63K	﹤0.01%	5238
2024 Q1	–	Sell	-2	Closed	-$9	–	5691
2023 Q4	$9	Buy	+2	New	+$8	﹤0.01%	5639
2016 Q2	–	Sell	-2	Closed	-$3K	–	7145
2016 Q1	$3K	Buy	+2	New	+$3.5K	﹤0.01%	7126

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citigroup's EDSA Position: Q2 2026 in Review

Citigroup sold out of Edesa Biotech (EDSA) in Q2 2026, closing a stake of 487 shares — an estimated $2.55K sold.

Citigroup first reported a position in EDSA in Q1 2016 and held it in 4 quarters. The position peaked at $4.88K in Q3 2025. 33 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

Citigroup reported no remaining Edesa Biotech position as of Q2 2026 after selling out during the quarter.
Citigroup sold 487 Edesa Biotech shares in Q2 2026, an estimated $2.55K.
Citigroup first reported a position in Edesa Biotech in Q1 2016 and held it in 4 quarters.
Citigroup's Edesa Biotech position peaked at $4.88K in Q3 2025.
33 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.